News
LNTH
83.92
-0.02%
-0.02
Lantheus Holdings Price Target Raised to $98.00/Share From $89.00 by Truist Securities
Dow Jones · 1d ago
Lantheus Holdings Is Maintained at Buy by Truist Securities
Dow Jones · 1d ago
Lantheus price target raised to $98 from $89 at Truist
TipRanks · 1d ago
LANTHEUS HOLDINGS INC <LNTH.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $98 FROM $89
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Autodesk, Citigroup, Wells Fargo
Reuters · 1d ago
Lantheus Holdings Is Maintained at Outperform by Mizuho
Dow Jones · 3d ago
Lantheus Holdings Price Target Raised to $95.00/Share From $85.00 by Mizuho
Dow Jones · 3d ago
Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $95
Benzinga · 3d ago
Lantheus price target raised to $95 from $85 at Mizuho
TipRanks · 3d ago
LANTHEUS HOLDINGS INC <LNTH.O>: MIZUHO RAISES TARGET PRICE TO $95 FROM $85
Reuters · 3d ago
Weekly Report: what happened at LNTH last week (0406-0410)?
Weekly Report · 3d ago
U.S. RESEARCH ROUNDUP-Chevron, Ford, Occidental Petroleum
Reuters · 3d ago
3 Profitable Stocks We Think Twice About
Barchart · 04/09 03:26
3 Cash-Producing Stocks Walking a Fine Line
Barchart · 04/08 04:46
Lantheus Holdings: Tensions From The PDUFA Extension
Seeking Alpha · 04/07 12:53
Weekly Report: what happened at LNTH last week (0330-0403)?
Weekly Report · 04/06 09:33
Weekly Report: what happened at LNTH last week (0323-0327)?
Weekly Report · 03/30 09:33
3 Russell 2000 Stocks We’re Skeptical Of
Barchart · 03/25 02:16
Weekly Report: what happened at LNTH last week (0316-0320)?
Weekly Report · 03/23 09:31
BUZZ-U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
Reuters · 03/18 15:47
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.